Horizon Technology Finance Management, LLC is a venture lending firm that specializes in providing structured debt products, including senior and subordinated venture loans, secured working capital loans, and equipment loans, to development-stage companies primarily in the technology and life sciences sectors. Founded in 2003 and headquartered in Farmington, Connecticut, with additional offices in Pleasanton, California, and Reston, Virginia, Horizon focuses on investments in areas such as cloud computing, biotechnology, and alternative energy. The firm targets companies in the Mid-Atlantic and Western regions of the United States, offering loans ranging from $1 million to $25 million, with repayment terms of up to 48 months. With a team that has collectively originated over $5 billion in venture loans, Horizon aims to support innovative companies by providing essential capital to fuel their growth.
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.